4D Molecular Therapeutics Reports Officer/Director Changes, Comp. Arrangements
Ticker: FDMT · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | 8-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-change, compensation, corporate-governance
TL;DR
**4D Molecular Therapeutics just reported executive changes and new pay deals, watch for details.**
AI Summary
4D Molecular Therapeutics, Inc. filed an 8-K on January 4, 2024, reporting an event that occurred on January 1, 2024, related to changes in directors or officers and their compensation. This filing indicates potential shifts in leadership or executive compensation structures, which could impact the company's strategic direction and financial health. Investors should monitor subsequent filings for details on who departed or was appointed and the specifics of any new compensatory arrangements, as these changes can influence future performance and stock valuation.
Why It Matters
Changes in executive leadership or compensation can signal strategic shifts or financial adjustments, directly influencing investor confidence and the company's operational stability.
Risk Assessment
Risk Level: medium — Without specific details on the personnel changes or compensation, the impact is uncertain, posing a moderate risk to investors.
Analyst Insight
A smart investor would await further details on the specific departures, appointments, and compensatory arrangements before making any investment decisions, as this filing is currently lacking critical information.
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 1, 2024 (date) — date of the earliest event reported
- January 4, 2024 (date) — date the 8-K was filed
- 001-39782 (string) — Commission File Number
- 5858 Horton Street #455 Emeryville, California 94608 (string) — principal executive offices address
- (510) 505-2680 (string) — registrant's telephone number
Forward-Looking Statements
- Further details regarding the specific personnel changes and compensation arrangements will be disclosed in subsequent filings or press releases. (4D Molecular Therapeutics, Inc.) — high confidence, target: Q1 2024
- The market will react to the specifics of the executive changes once they are fully disclosed. (4D Molecular Therapeutics, Inc. stock) — medium confidence, target: Q1 2024
FAQ
What specific event did 4D Molecular Therapeutics, Inc. report in this 8-K filing?
The 8-K filing reports events related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' as per Item 5.02.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on January 1, 2024.
What is the business address of 4D Molecular Therapeutics, Inc. as stated in the filing?
The business address of 4D Molecular Therapeutics, Inc. is 5858 Horton Street #455, Emeryville, California 94608.
What is the Commission File Number for 4D Molecular Therapeutics, Inc.?
The Commission File Number for 4D Molecular Therapeutics, Inc. is 001-39782.
What is the primary purpose of an 8-K filing, as indicated by the form's title?
The form's title, 'CURRENT REPORT,' indicates that an 8-K filing is used to announce major events that shareholders should know about, typically within four business days of the event.
Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-01-04 08:30:59
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share FDMT NASDAQ Glo
Filing Documents
- d624050d8k.htm (8-K) — 23KB
- 0001193125-24-001977.txt ( ) — 142KB
- fdmt-20240101.xsd (EX-101.SCH) — 3KB
- fdmt-20240101_lab.xml (EX-101.LAB) — 18KB
- fdmt-20240101_pre.xml (EX-101.PRE) — 11KB
- d624050d8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective as of January 2, 2024, Noriyuki Kasahara, M.D., Ph.D., has been appointed by the Board of Directors (the "Board") of 4D Molecular Therapeutics, Inc. (the "Company") as Chief Scientific Officer of the Company. On January 1, 2024, Dr. Kasahara delivered notice of his resignation from the Board of the Company, including his role as a member and the Chair of the Science and Technology Committee of the Board, effective on January 1, 2024. Dr. Kasahara's resignation from the Board is not a result of a disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 4D MOLECULAR THERAPEUTICS, INC. Date: January 4, 2024 By: /s/ Uneek Mehra Uneek Mehra Chief Financial and Business Officer